Welcome to our dedicated page for BioSig Technologies SEC filings (Ticker: BSGM), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Reading BioSig’s filings can feel like scrubbing through hundreds of pages of electrophysiology jargon just to confirm one clinical-trial milestone. Stock Titan removes that friction by turning every BioSig Technologies SEC document into plain language insights, updated the moment they reach EDGAR.
Our AI engine pinpoints what investors ask for most—including R&D spend buried in a BioSig Technologies quarterly earnings report 10-Q filing, FDA feedback disclosed in an 8-K material events explained note, and dilution risks outlined in a BioSig Technologies annual report 10-K simplified. You’ll also get real-time alerts on BioSig Technologies Form 4 insider transactions real-time so you can track when executives trade shares around pivotal PURE EP announcements.
Skip the slog of cross-referencing forms. Stock Titan links each question to the right filing type:
- Form 4: BioSig Technologies insider trading Form 4 transactions & BioSig Technologies executive stock transactions Form 4
- 10-Q: Quarterly revenue trends and BioSig Technologies earnings report filing analysis
- 10-K: Cash runway, IP status, and risk factors—BioSig Technologies SEC filings explained simply
- DEF 14A: BioSig Technologies proxy statement executive compensation
Whether you’re understanding BioSig Technologies SEC documents with AI for the first time or benchmarking peer med-tech disclosures, our platform delivers AI-powered summaries, keyword search across every exhibit, and expert commentary you can trust. Make faster, evidence-based decisions without decoding electrophysiology vocabulary on your own.
Frank Giustra, a director and 10% owner of Streamex Corp. (STEX), reported multiple purchases of the issuer's common stock executed on 07/25/2025 and 08/14/2025. The filings show four purchases on July 25 totaling 50,000 shares at prices between $4.64 and $4.72, and a later purchase on August 14 of 128,205 shares at $3.90, bringing the reported beneficial ownership to 178,205 shares. The shares are held indirectly through Sestini & Co., an entity controlled by the reporting person, as disclosed in the explanation. There are no derivative securities reported on this form. The document is signed by the reporting person on 09/15/2025.
The filing is an initial Form 3 by Frank Giustra reporting indirect beneficial ownership in Streamex Corp. (STEX). Mr. Giustra beneficially holds 17,193,640 Exchangeable Shares that are exchangeable into Common Stock of the issuer. Approximately 5.01% of the Exchangeable Shares are currently exchangeable into Common Stock, with the remaining Exchangeable Shares becoming exchangeable upon a pending stockholder approval expected within 60 days. Nasdaq rules limit exchanges to 19.9% of outstanding Common Stock until stockholder approval is obtained.
BioSig Technologies, Inc. (BSGM) filed an Form 8-K dated September 5, 2025 reporting corporate governance actions. The filing lists Item 5.03 (submission of matters to a vote of security holders) and includes two exhibits: a Ninth Certificate of Amendment (Exhibit 3.1) and an Incentive Plan Amendment (Exhibit 10.1). The cover page also references an Inline XBRL interactive data file. The form is signed by Karl Henry McPhie, Chief Executive Officer.
BioSig Technologies (BSGM) reported a substantial net loss of $20,368 and $23,169 for the three- and six-month periods presented, respectively, and a working capital deficit of $110 million, which management states raises substantial doubt about the company’s ability to continue as a going concern. The balance sheet includes a $105,498 derivative/Exchangeable Shares liability that remains classified as a liability because shareholder approval and other contingencies have not been resolved. The company completed the acquisition of Streamex, recording $57.8 million of goodwill and material intangible assets (developed technology and legal/compliance framework). Financing and equity activity during the period included multiple stock offerings, an at-the-market program raising net proceeds of about $3.88 million, and extensive issuance of common stock, RSUs, warrants, and preferred cumulative dividends recorded.